These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37273124)

  • 21. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
    J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
    Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy and cardiovascular risk in prostate cancer.
    DE Nunzio C; Fiori C; Fusco F; Gregori A; Pagliarulo V; Alongi F
    Minerva Urol Nephrol; 2022 Oct; 74(5):508-517. PubMed ID: 35470648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
    Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
    JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update].
    von Amsberg G; Thiele H; Merseburger A
    Urologe A; 2021 Nov; 60(11):1450-1457. PubMed ID: 34213627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
    Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
    Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
    Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
    Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy and cardiovascular complications.
    Poljak Z; Hulin I; Maruscakova L; Carter A; Mladosievicova B
    Bratisl Lek Listy; 2016; 117(10):557-561. PubMed ID: 28621142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
    Liu R; Zhou J; Xia S; Li T
    Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation therapy for prostate cancer: new concepts and concerns.
    Smith MR
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):247-54. PubMed ID: 17940447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Solanki AJ; Kamrava M; Posadas EM; Freedland SJ; Ballas L; Sandler HM; Bairey Merz CN; Atkins KM; Nikolova AP
    Cancer; 2024 Jun; 130(11):1916-1929. PubMed ID: 38529566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
    Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
    Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.